This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Thirteen patients in the intervention group and 18 in the control group discontinued treatment.
Analysis of effectiveness
The analysis of effectiveness was based on intention to treat. The chief clinical outcome was the change in the severity of the reflux symptoms measured by a visual analogue scale (VAS) at 4 weeks. The adverse effects of the treatment modalities were reported. The study groups were shown to be comparable except in terms of the number of cigarettes per day; it was reported that an adjustment for this factor did not change the results.
Effectiveness results
In terms of VAS at 4 weeks, the intervention group experienced an average improvement of 62 versus 53 in the control group, (p=0.005). The adverse effects were reported to be rare and not serious (22 events in 13 patients in the intervention group as opposed to 27 events in 23 patients in the control group).
Clinical conclusions
"The results are very homogenous, with all the evaluation criteria in favour of the alginate".
Measure of benefits used in the economic analysis
The measure of benefit was the change in the severity of the reflux symptoms measured by a visual analogue scale (VAS) at 4 weeks. The patients evaluated their own state of health.
Direct costs
Discounting of costs was not required due to the short period of treatment. Resource use data were not reported separately from the costs. Cost items were reported in two general categories. The cost analysis consisted of the administration costs of the treatments and the costs associated with co-prescriptions, prescription for treatment failures, side-effects, and intercurrent effects. The perspective adopted in the cost analysis was not explicitly specified. The source of resource and cost data was actual data. The cost analysis did not include the costs of consultations, endoscopies, blood analyses, and electrocardiograms as these were similar for both alternatives. The date of the price data was not explicitly specified.
Indirect Costs
Costs were not required to be discounted due to the short period of treatment. Quantities were not reported. The number of working days lost was registered during the trial. Details of the methods of cost calculations for the lost earnings were not given. The date of the price data was not explicitly specified.
Currency
French francs (Ffr) . No conversion to other currencies was reported.
Sensitivity analysis
Sensitivity analyses, including a per protocol analysis, were reported to have been performed, but they did not affect the results.
Estimated benefits used in the economic analysis
In terms of VAS at 4 weeks, the intervention group experienced an average improvement of 62 versus 53 in the control group, (p=0.005).
